<?xml version="1.0" encoding="UTF-8"?>
<p>Under a TRIPS-compliant patent regime, WTO member states are required to guarantee product patents and exclusive marketing rights to innovators. These expanded patent protections enable pharmaceutical companies to set high prices, which help companies recoup R&amp;D costs but also often put medicines out of reach for the poor. For this reason, former World Bank Chief Economist Joseph Stiglitz has described the TRIPS Agreement as “a death warrant for thousands of people in the poorest countries of the world” [
 <xref rid="R4" ref-type="bibr">4</xref>].
</p>
